Replies to post #1363 on Aradigm Corp fka ARDMQ

[Sage7243]

2 month reduction in SEVERE pulmonary events.

In other words, severe costs more money. Preventing them SAVES Money.

I listened to webcast and learned a lot.

Been sitting on sidelines for years. I joined in today. I sold Grifols and put $$$ in $ARDM.

https://event.webcasts.com/viewer/event.jsp?ei=1130387

[drugmanrx]

How old is the data of this article. The results of the two phase 3 studies have been posted for a month.


https://www.dvidshub.net/news/219852/changing-tide-antibiotic-resistant-infections

Pulmaquin is currently undergoing two Phase 3 clinical studies to determine its safety and effectiveness as an inhaled formulation for the treatment of patients with non-cystic fibrosis bronchiectasis, cystic fibrosis or non-tuberculous mycobacteria. However, Pulmaquin and an alternate formulation, Lipoquin, both demonstrated proof-of-concept efficacy in rodent models of inhalational tularemia, plague and Q-fever.

It was the result of one of the studies that drove down the price.

http://www.businesswire.com/news/home/20161201005450/en/Aradigm-Announces-Top-Line-Results-Phase-3-Studies